Effects of epinephrine in patients with an accessory atrioventricular connection treated with quinidine.
The purpose of this study was to determine whether physiologic doses of epinephrine reverse the electrophysiologic effects of quinidine in patients with an accessory atrioventricular (AV) connection. Eighteen patients with an accessory AV connection who had inducible sustained orthodromic tachycardia underwent an electrophysiologic study in the baseline state and after at least 2 days of treatment with 1.4 to 1.9 g/day of quinidine gluconate. The effects of epinephrine were then determined. Epinephrine infusion rates of 25 and 50 ng/kg/min were used in 9 patients each because these doses of epinephrine previously have been demonstrated to result in elevated plasma epinephrine concentrations in the range that occurs during a variety of stresses in humans. Quinidine prolonged refractoriness in the atrium and accessory AV connection and slowed conduction through the accessory AV connection. These effects were partially or completely reversed by epinephrine. Among 8 patients in whom quinidine resulted in orthodromic tachycardia becoming noninducible or nonsustained, sustained tachycardia became inducible again in 5 patients after infusion of epinephrine. After quinidine, atrial fibrillation was either noninducible or nonsustained in 8 patients; however, sustained atrial fibrillation could be induced in 4 of these patients after infusion of epinephrine. The results of this study demonstrate that the therapeutic effect of quinidine in patients who have an accessory AV connection are often reversed by physiologic increases in circulating epinephrine.
Morady
F
F
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor.
Kou
W H
WH
Kadish
A H
AH
Toivonen
L K
LK
Kushner
J A
JA
Schmaltz
S
S
D000328:Adult; D001281:Atrial Fibrillation / Q000503:physiopathology; D001283:Atrioventricular Node / Q000503:physiopathology*; D004562:Electrocardiography; D004594:Electrophysiology; D004837:Epinephrine / Q000494:pharmacology*; D005260:Female; D006329:Heart Conduction System / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011802:Quinidine / Q000627:therapeutic use*; D013610:Tachycardia / Q000188:drug therapy / Q000503:physiopathology*
D011802:Quinidine; D004837:Epinephrine